NCT01517568View on ClinicalTrials.gov

Metabolism and Excretion of Liraglutide in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions

DiabetesHealthy

Interventions

DRUG

liraglutide [3H]

A single dose of 0.75 mg will be given as a subcutaneous injection

Trial Locations (1)

9728 NZ

Novo Nordisk Investigational Site, Groningen

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY